Canada Archives

Best in Biotech 1 Dec 2022

Five apps powering the future of at-home HIV tests

The smartphone revolution is providing a promising tool to combat the human immunodeficiency virus (HIV) epidemic. We’ve listed five HIV test apps in development that could help people carry out at-home HIV tests and prevent the spread of the infection. The COVID-19 pandemic in the last two years has demonstrated how vital rapid diagnostic tests […]

December 1, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 18 Nov 2022

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […]

November 18, 2022 - 2 minutesmins - By Liza Laws

Best in Biotech 17 Nov 2022

The hottest private biotech companies in Canada

Canada is well known for biotech innovations, with expertise in genomics, cell therapies and liquid biopsy. Here is a list of private healthcare biotech companies that have attracted big cash in Canada in the past two years. Canada has one of the top 10 biggest economies in the world. The developed country boasts rich forests, […]

November 17, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 2 Nov 2022

Could DNA nanotransporters treat cancer?

A team of Canadian researchers from Université de Montréal has designed and validated a new class of drug transporters made of DNA 20,000 times smaller than a human hair. The DNA nanotransporters could improve how cancers and other diseases are treated. Reported in a new study in Nature Communications, the molecular transporters can be chemically […]

November 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 25 Oct 2022

Delayed release tablets to treat ulcerative colitis launched in Canada

With Canada having one of the highest incidences of ulcerative colitis in the world, the recent launch of Tillotts Pharma AG’s Octasa 800 mg will be well-received. Tillotts is part of the Japanese Zeria Group, and announced Octasa (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada. The launch, the […]

October 25, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Oct 2022

Distributor of Curcugen and Ginfort receives dual natural product licenses

Two Health Canada natural product licenses have been achieved by DolCas Biotech LLC and have been found safe, effective and high quality. The products are its concentrated turmeric extract, Curcugen, and the other for Ginfort, a powerful ginger extract in powdered format. Produced by Olene Life Sciences, the two ingredient brands are research-backed for clinical […]

October 25, 2022 - 4 minutesmins - By Liza Laws

More News! 24 Oct 2022

Mass production of lutetium for targeted cancer therapeutics following collaboration

An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […]

October 24, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Sunshine Biopharma acquires Nora Pharma

Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. Nora Pharma is now a wholly owned subsidiary of Sunshine Biopharma Inc. The addition of Nora Pharma allows Sunshine Biopharma to expand […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market

Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16, a proposed biosimilar to an undisclosed immunology product and AVT33, a proposed biosimilar to an undisclosed oncology product. “We are very pleased to be expanding […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

Amgen joining Evotec and TIAP to boost Canadian life science companies

Evotec SE and Toronto Innovation Acceleration Partners (TIAP) have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of $14 million to expedite LAB150 programs towards the formation of new companies. LAB150 was created by Evotec and TIAP in 2017 to accelerate Toronto’s […]

October 17, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia

The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us